Jahn M Nesland Selected Research

Carcinoma (Carcinomatosis)

01/2008	Death receptor expression is associated with poor response to chemotherapy and shorter survival in metastatic ovarian carcinoma.
04/2007	Expression of seprase in effusions from patients with epithelial ovarian carcinoma.
09/2006	Subcellular localization pattern of protoporphyrin IX is an important determinant for its photodynamic efficiency of human carcinoma and normal cell lines.
09/2006	The mitogen-activated protein kinases (MAPK) p38 and JNK are markers of tumor progression in breast carcinoma.
08/2006	p14ARF, a prognostic predictor in HPV-negative vulvar carcinoma.
07/2006	Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma.
04/2006	An increase in the number of adhesion proteins with altered expression is associated with an increased risk of cancer death for colon carcinoma patients.
01/2006	Induction of apoptosis by hexaminolevulinate-mediated photodynamic therapy in human colon carcinoma cell line 320DM.
06/2005	Cyclins D1, D3, E, and A in vulvar carcinoma patients.
07/2004	Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma.
05/2004	The PAC-1 dual specificity phosphatase predicts poor outcome in serous ovarian carcinoma.
01/2004	Altered expression and activation of the nerve growth factor receptors TrkA and p75 provide the first evidence of tumor progression to effusion in breast carcinoma.
10/2003	Mitogen-activated protein kinases (MAPK) as predictors of clinical outcome in serous ovarian carcinoma in effusions.
06/2003	Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma.
01/2003	Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): co-expression in metastatic serous ovarian carcinoma.
05/2002	Type 1 protein tyrosine kinases in breast carcinoma: a review.
04/2002	The expression of EGFR family ligands in breast carcinomas.
02/2002	The prognostic value of metalloproteinases and angiogenic factors in ovarian carcinoma.
02/2002	Caveolin-1 expression in ovarian carcinoma is MDR1 independent.
01/2002	Interleukin-8 and vascular endothelial growth factor mRNA and protein levels are down-regulated in ovarian carcinoma cells in serous effusions.

Articles by Research Topic

Disease

20	Carcinoma (Carcinomatosis) 01/2008 - 01/2002
7	Neoplasms (Cancer) 10/2006 - 05/2002
4	Breast Neoplasms (Breast Cancer) 06/2006 - 04/2003
2	Ovarian Neoplasms (Ovarian Cancer) 10/2007 - 05/2005
2	Mesothelioma 07/2007 - 07/2006
2	Tissue Adhesions 10/2006 - 04/2006
2	Melanoma (Melanoma, Malignant) 08/2004 - 08/2003
1	Anoxia (Hypoxia) 12/2006
1	Lymphoma (Lymphomas) 11/2006
1	Experimental Melanoma 07/2006
1	Neoplasm Metastasis (Metastasis) 07/2006
1	Leukemia 12/2005
1	Adenocarcinoma 01/2004
1	Nerve Sheath Neoplasms (Nerve Sheath Neoplasm) 12/2003
1	Germ Cell and Embryonal Neoplasms (Germ Cell Tumor) 11/2003
1	Prostatic Neoplasms (Prostate Cancer) 01/2003

Drug/Important Bio-Agent (IBA)

4	beta CateninIBA 10/2006 - 08/2003
3	5-aminolevulinic acid hexyl esterIBA 11/2006 - 12/2005
3	Mitogen-Activated Protein KinasesIBA 09/2006 - 01/2003
2	gamma Catenin (Plakoglobin)IBA 10/2006 - 01/2004
2	Cadherins (E-Cadherin)IBA 10/2006 - 08/2004
2	Proteins (Proteins, Gene)IBA 10/2006 - 04/2006
2	Codon (Codons)IBA 07/2004 - 11/2003
2	Matrix MetalloproteinasesIBA 01/2003 - 05/2002
1	EphA1 Receptor (Eph Receptor)IBA 10/2007
1	Inhibitor of Apoptosis ProteinsIBA 07/2007
1	fibroblast activation protein alphaIBA 04/2007
1	cobaltous chloride (cobalt(II)chloride)IBA 12/2006
1	Edetic Acid (EDTA)FDA Link 10/2006
1	GelatinasesIBA 10/2006
1	alpha Catenin (alpha E-Catenin)IBA 10/2006
1	protoporphyrin IXIBA 09/2006
1	p38 Mitogen-Activated Protein KinasesIBA 09/2006
1	Tumor Suppressor Protein p14ARF (p14ARF)IBA 08/2006
1	Thromboplastin (Tissue Factor)IBA 07/2006
1	HLA-G antigen (HLA G)IBA 07/2006
1	RNA (Ribonucleic Acid)IBA 07/2006
1	Apoptosis Inducing FactorIBA 12/2005
1	CyclinsIBA 06/2005
1	DNA (Deoxyribonucleic Acid)IBA 05/2005
1	Thymidine PhosphorylaseIBA 11/2004
1	Thymidylate SynthaseIBA 11/2004
1	Dihydrouracil Dehydrogenase (NADP) (Dihydropyrimidine Dehydrogenase)IBA 11/2004
1	Dual-Specificity PhosphatasesIBA 05/2004
1	Cyclin D1IBA 01/2004
1	Nerve Growth Factor Receptors (Neurotrophin Receptors)IBA 01/2004
1	DNA topoisomerase II alphaIBA 12/2003
1	Proto-Oncogene Proteins c-kit (Proto-Oncogene Protein c-kit)IBA 11/2003
1	Cyclin AIBA 07/2003
1	Nerve Growth Factor Receptor (Nerve Growth Factor Receptor, Low Affinity)IBA 06/2003
1	HormonesIBA 04/2003
1	CD147 Antigens (Basigin)IBA 01/2003
1	Keratins (Keratin)IBA 01/2003
1	Carbon MonoxideIBA 01/2003
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 05/2002
1	LigandsIBA 04/2002
1	Metalloproteases (Metalloproteinases)IBA 02/2002
1	Caveolin 1IBA 02/2002
1	Messenger RNA (mRNA)IBA 01/2002
1	Interleukin-8 (Interleukin 8)IBA 01/2002
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2002

Therapy/Procedure

5	Photochemotherapy (Photodynamic Therapy) 12/2006 - 09/2004
2	Drug Therapy (Chemotherapy) 01/2008 - 06/2006